Ascendis Pharma A/s Stock News

Ascendis Pharma (ASND) gets nod in Europe for TransCon hGH for the treatment of pediatric growth hormone deficiency.

Ascendis Pharma (ASND) gets nod in Europe for TransCon hGH for the treatment of pediatric growth hormone deficiency.

The European Commission (EC) has granted marketing authorization to Ascendis Pharma A/S''s (NASDAQ: ASND ) Lonapegsomatropin (developed under the name TransCon hGH). The approval for TransCon covers a once-weekly subcutaneous injection for children and adolescents ages 3 to 18 years with Full story available on Benzinga.com

Ascendis Pharma <> said the European Commission approved Lonapegsomatropin (developed under the name TransCon hGH) as a once-weekly subcutaneous injection to treat children ages 3

The European Commission (EC) has granted marketing authorization to Ascendis Pharma A/S's (NASDAQ: ASND) Lonapegsomatropin (developed under the name TransCon hGH). The approval for TransCon covers a

Analysts have provided the following ratings for Ascendis Pharma (NASDAQ: ASND ) within the last quarter:

Look for surprise values in underpriced stocks. Not the story issues being ballyhooed by touts and the media - everyone knows them.

Wall Street analysts expect that Ascendis Pharma A/S (NASDAQ:ASND) will post sales of $4.34 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Ascendis Pharma A/Ss earnings, with the highest sales estimate coming in at $9.63 million and the lowest estimate coming in at $930,000.00. Ascendis Pharma A/S []

–– TransCon™ PTH Phase 3 topline results expected in Q1 2022 and, if positive, planned NDA submission in Q3 2022 followed by expected MAA submission in Q4 2022 –– Enrollment completed in Phase 2 ACcomplisH Trial of TransCon CNP; blinded data informed dose selection of 50 and 100 μ g/kg/week in

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have been assigned an average rating of Buy from the thirteen brokerages that are currently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 12 month price objective among brokerages []

Equities researchers at Wells Fargo & Company began coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a note issued to investors on Wednesday, PriceTargets.com reports. The brokerage set an overweight rating and a $176.00 price target on the biotechnology companys stock. Wells Fargo & Companys target price indicates a potential upside of 26.03% from []

Parametric Portfolio Associates LLC increased its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 38.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,565 shares of the biotechnology companys stock after buying an additional 7,620 shares during the quarter. Parametric []

COPENHAGEN, Denmark, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will host a virtual R&D Program Update for the investment community on Tues

COPENHAGEN, Denmark , Dec. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will host a virtual R&D Program Update for the investment community on Tuesday, December 14, 2021 . The event will feature updates on Ascendis Pharmas endocrinology rare

Wall Street analysts expect Ascendis Pharma A/S (NASDAQ:ASND) to announce $4.34 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Ascendis Pharma A/Ss earnings, with estimates ranging from $930,000.00 to $9.63 million. Ascendis Pharma A/S posted sales of $640,000.00 in the same quarter last year, []